March 21, 2019

UsAgainstAlzheimer’s Statement on Discontinuation of Clinical Trials for Aducanumab

UsAgainstAlzheimer's Chairman George Vradenburg issued the following statement today regarding the termination of phase II and phase III clinical trial testing of the Alzheimer's drug aducanumab by Biogen and Eisai.

July 22, 2018

New Analysis Provides Insights into Late-Stage Alzheimer’s Drug Pipeline

ResearchersAgainstAlzheimer’s calls on governments, industry, entrepreneurs, and world leaders to improve healthcare system to respond to today’s patients and caregivers and accommodate future Alzheimer’s disease treatments  

Thumbnail

Single Endpoint for New Drug Approvals for Alzheimer’s Disease

The Food and Drug Administration’s (FDA) approach to approving new medicines for Alzheimer’s disease since the 1990s has been to require a proven benefit on two independent primary endpoints of cognition and function, although this policy has not been formalized...

Download Report
February 20, 2018 - George Vradenburg

At Least Alzheimer's Research Is Bringing Washington Together

This op-ed originally appear in The Hill newspaper on February 15, 2018. In an era of extreme partisanship, there is one issue that continues to inspire collaboration and even comradery among members of both parties: the fight to stop Alzheimer’s. Click here to continue reading.
Thumbnail

RA2’s Phase 3 Pipeline Analysis (March 2016)

Success in drug development for Alzheimer’s disease has been elusive. Recent analysis has shown a near 100% failure rate in the past decade.

Download Report
Thumbnail

RA2’s Phase 2 Pipeline Analysis (September 2016)

A Diverse Phase 2 Pipeline of Alzheimer’s Drugs Promises New Innovations and New Challenges
Download Report